Russell Investments Group
DNLI icon

Russell Investments Group’s Denali Therapeutics DNLI Stock Holding History

Russell Investments Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
86,032
+71,974
+512% +$1.48M ﹤0.01% 2036
2026
Q1 		$270K Buy
14,058
+591
+4% +$11.8K ﹤0.01% 2746
2025
Q4 		$222K Sell
13,467
-332
-2% -$5.6K ﹤0.01% 2810
2025
Q3 		$200K Buy
13,799
+11,241
+439% +$162K ﹤0.01% 2812
2025
Q2 		$35.8K Sell
2,558
-83
-3% -$1.17K ﹤0.01% 3060
2025
Q1 		$35.9K Sell
2,641
-19,475
-88% -$373K ﹤0.01% 2978
2024
Q4 		$451K Buy
22,116
+142
+0.6% +$3.63K ﹤0.01% 2302
2024
Q3 		$640K Sell
21,974
-940
-4% -$23.3K ﹤0.01% 2196
2024
Q2 		$532K Sell
22,914
-62,714
-73% -$1.2M ﹤0.01% 2175
2024
Q1 		$1.76M Sell
85,628
-25,845
-23% -$486K ﹤0.01% 1711
2023
Q4 		$2.39M Sell
111,473
-2,585
-2% -$51.2K ﹤0.01% 1517
2023
Q3 		$2.35M Buy
114,058
+7,244
+7% +$184K ﹤0.01% 1456
2023
Q2 		$3.15M Buy
106,814
+24,519
+30% +$689K 0.01% 1303
2023
Q1 		$1.9M Sell
82,295
-17,078
-17% -$470K ﹤0.01% 1618
2022
Q4 		$2.76M Sell
99,373
-7,488
-7% -$223K 0.01% 1389
2022
Q3 		$3.28M Buy
106,861
+18,631
+21% +$606K 0.01% 1290
2022
Q2 		$2.6M Buy
88,230
+36,710
+71% +$962K 0.01% 1447
2022
Q1 		$1.66M Sell
51,520
-14,601
-22% -$502K ﹤0.01% 1729
2021
Q4 		$2.95M Buy
66,121
+770
+1% +$36.5K ﹤0.01% 1586
2021
Q3 		$3.28M Buy
65,351
+1,594
+3% +$89.8K 0.01% 1506
2021
Q2 		$4.99M Buy
63,757
+15,791
+33% +$977K 0.01% 1354
2021
Q1 		$2.73M Sell
47,966
-32,129
-40% -$2.15M ﹤0.01% 1709
2020
Q4 		$6.71M Buy
80,095
+25,496
+47% +$1.54M 0.01% 1079
2020
Q3 		$1.96M Hold
54,599
– – ﹤0.01% 1703
2020
Q2 		$1.32M Sell
54,599
-17,130
-24% -$403K ﹤0.01% 1886
2020
Q1 		$1.25M Sell
71,729
-45,190
-39% -$943K ﹤0.01% 1732
2019
Q4 		$2.04M Buy
116,919
+47,796
+69% +$796K ﹤0.01% 1731
2019
Q3 		$1.06M Buy
69,123
+33,583
+94% +$642K ﹤0.01% 1980
2019
Q2 		$736K Buy
35,540
+9,650
+37% +$216K ﹤0.01% 2116
2019
Q1 		$601K Buy
25,890
+9,094
+54% +$190K ﹤0.01% 2282
2018
Q4 		$347K Buy
+16,796
New +$305K ﹤0.01% 2435

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Russell Investments Group's DNLI Position: Q2 2026 in Review

Russell Investments Group increased its Denali Therapeutics (DNLI) stake by 512% in Q2 2026, buying an estimated $1.48M and bringing the position to 86,032 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2036.

Russell Investments Group first reported a position in DNLI in Q4 2018 and has held it in 31 quarters since. The position peaked at $6.71M in Q4 2020. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Russell Investments Group held 86,032 shares of Denali Therapeutics worth $2.21M as of Q2 2026.
  • Russell Investments Group bought 71,974 Denali Therapeutics shares in Q2 2026, an estimated $1.48M.
  • Denali Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2036 holding.
  • Russell Investments Group first reported a position in Denali Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Russell Investments Group's Denali Therapeutics position peaked at $6.71M in Q4 2020.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.